MASATAKA SUZUKI to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications MASATAKA SUZUKI has written about Xenograft Model Antitumor Assays.
Connection Strength
0.840
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
Score: 0.194
-
Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors. Commun Biol. 2021 03 19; 4(1):368.
Score: 0.150
-
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. 2020 05 06; 28(5):1251-1262.
Score: 0.139
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.118
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.113
-
Chick Embryo Chorioallantoic Membrane as a Platform for Assessing the In?Vivo Efficacy of Chimeric Antigen Receptor T-cell Therapy in Solid Tumors. Immunohorizons. 2024 08 01; 8(8):598-605.
Score: 0.047
-
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
Score: 0.037
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.025
-
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther. 2008 Sep; 16(9):1546-55.
Score: 0.016